SEC Form 4 · accession 0001104659-15-049025

CATABASIS PHARMACEUTICALS INC · CATB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Jun 30, 2015

Accepted (ET)

Jun 30, 2015 · 6:48 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001454789

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1	Jun 30, 2015	C	66,658	—	A	245,684	D
Common Stock^F1	Jun 30, 2015	C	409	—	A	246,093	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1	—	Jun 30, 2015	C	856,571	D	—	—	Common Stock	66,658	0	D
Series B Preferred Stock^F1	—	Jun 30, 2015	C	5,261	D	—	—	Common Stock	409	0	D

F1The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.